Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer
Yungan Tao, Valentina Pinzi, Jean Bourhis and Eric Deutsch*
Correspondence *Laboratory UPRES EA 27–10, Institute Gustave Roussy, 39 Rue Camille-Desmoulins, 94805 Villejuif, France
Email deutsch@igr.fr
The insulin-like growth factor 1 (IGF1) signaling pathway is implicated in the development of cancer. IGF1R signaling has been found to correlate with resistance to anti-EGFR and HER2-based therapies in experimental systems. This Review highlights the most relevant studies in this exciting area of research, focusing in particular on the role of the IGF1R in the resistance of other receptor-targeted therapies.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.